Melane Sampson, Author at BioTuesdays

Developments

PharmaJet’s innovative needle-free system chosen for WHO polio immunization campaign in Somalia

Closely-held PharmaJet announced that its Tropis Intradermal (ID) Needle-free System was selected by WHO for use in a house-to-house immunization campaign targeting more than 170,000 children, age four to 59 months, in...

June 27, 2024

Developments

Lyell announces promising clinical data in TNBC

Lyell Immunopharma (Nasdaq:LYELL) has reported initial clinical and translational data from its Phase 1 trial of LYL797, a first-generation reprogrammed ROR1 CAR T cell product candidate enhanced with proprietary anti...

June 26, 2024

Developments

ANEW reports European patent for novel gene sequence and delivery systems in neurodegenerative disease

ANEW Medical (NASDAQ:WENA) has been granted and issued a patent from the European Patent Office (EPO) for the patent application covering the company’s secreted Klotho gene sequence and gene delivery system, intended...

June 26, 2024

Feature

Candel enhancing cancer patient survival and quality of life with breakthrough viral immunotherapies

Candel Therapeutics (NASDAQ:CADL) is developing off-the-shelf multimodal viral immunotherapies for individualized systemic anti-tumor immune response, specific to the patient’s difficult-to-treat cancer, improving...

June 25, 2024

Developments

Entrada reports positive data from Phase 1 DMD trial

Entrada Therapeutics (NASDAQ:TRDA) has announced positive preliminary data from its Phase 1 clinical trial evaluating the safety and tolerability of a single dose of ENTR-601-44-101 in patients with Duchenne Muscular...

June 24, 2024

Developments

SOPHiA GENETICS expands oncology portfolio with new RAM application

SOPHiA GENETICS (NASDAQ:SOPH) has announced its new residual acute myeloid (RAM) application, SOPHiA DDM RAM Solution, supporting measurable residual disease (MRD) testing to help monitor cancer and outpace relapse. The...

June 24, 2024

Developments

Sage’s Phase 2 SURVEYOR study meets primary endpoint; reinforces cognitive impact of Huntington’s disease

Sage Therapeutics (NASDAQ:SAGE) announced its Phase 2 SURVEYOR study has met its primary endpoint showing a significant difference in HD-Cognitive Assessment Battery composite scores at baseline between healthy...

June 11, 2024

Executive Moves

Cantargia names Ton Berkien as CBO

Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) announced the recruitment of Ton Berkien as Chief Business Officer effective October 1. Mr. Berkien joins the management team at Cantargia with approximately 30 years of...

June 11, 2024

Developments

Viridian reports details of SC VRDN-003 Phase 3 clinical program for patients with TED

Viridian Therapeutics (NASDAQ:VRDN) announced details of its plans to initiate two Phase 3 clinical trials of its subcutaneous VRDN-003 product candidate for patients with active and chronic moderate-to-severe thyroid...

June 11, 2024

Developments

Innate Pharma announces positive outcomes from TELLOMAK Phase 2 Study

Innate Pharma S.A. (Euronext Paris:IPH; Nasdaq:IPHA) presented positive results from its Phase 2 TELLOMAK study with lacutamab in mycosis fungoides at the ASCO 2024 Annual Meeting in Chicago. The company reported that...

June 5, 2024

Author - Melane Sampson

PharmaJet’s innovative needle-free system chosen for WHO polio immunization campaign in Somalia

Lyell announces promising clinical data in TNBC

ANEW reports European patent for novel gene sequence and delivery systems in neurodegenerative disease

Candel enhancing cancer patient survival and quality of life with breakthrough viral immunotherapies

Entrada reports positive data from Phase 1 DMD trial

SOPHiA GENETICS expands oncology portfolio with new RAM application

Sage’s Phase 2 SURVEYOR study meets primary endpoint; reinforces cognitive impact of Huntington’s disease

Cantargia names Ton Berkien as CBO

Viridian reports details of SC VRDN-003 Phase 3 clinical program for patients with TED

Innate Pharma announces positive outcomes from TELLOMAK Phase 2 Study

Subscribe